IMMUNOHISTOCHEMICAL CHARACTERISTICS OF ENDOMETRIAL TISSUES IN HYPERPLASTIC PROCESSES

  2. 2023
  3. IMMUNOHISTOCHEMICAL CHARACTERISTICS OF ENDOMETRIAL TISSUES IN HYPERPLASTIC PROCESSES

Tsyndrenko N. L., Lyndin M. S., Hyriavenko N. I., Sikora K. O., Tsepochko D. H., Romaniuk A. M.

IMMUNOHISTOCHEMICAL CHARACTERISTICS OF ENDOMETRIAL TISSUES IN HYPERPLASTIC PROCESSES

Show/Download

About the author:

Tsyndrenko N. L., Lyndin M. S., Hyriavenko N. I., Sikora K. O., Tsepochko D. H., Romaniuk A. M.

Heading:

PATHOMORPHOLOGY

Type of article:

Scientific article

Annotation:

Hyperplastic processes of the endometrium (HPE) are a common pathology of the female reproductive system. Excess estrogenic stimulation is a significant role in their development in the case of insufficient progesterone influence. Estrogen receptors (ER) alpha are the main isoforms that mediate endometrial proliferation in hyperplastic processes. Our study aimed to determine the degree of ER expression in different types of HPE and to study the dependence of their expression on the histological variant and anthropometric indicators. Tissue samples were divided into groups depending on the obtained result of histological examination, namely, atypical endometrial hyperplasia, endometrial glandular polyps, and endometrial glandular-fibrous polyps. It has been established that endometrial glandular polyps occur at a younger age compared to atypical endometrial hyperplasia and glandular-fibrous endometrial polyps. In general, there is a tendency to increase the body mass index in women with HPE. There is no dependence of the type of endometrial hyperplastic processes on growth, body weight, and body mass index. Researching the expression of ER revealed a violation of the receptor status in HPE in the form of their uneven expression in the epithelial and stromal components. An increase in the expression of ER in the endometrial glands compared with the stroma was found to be uneven in intensity and concentration. Violation of the receptor status in hyperplastic processes of the endometrium is characterized by uneven expression of ER in the epithelial and stromal components. Uneven expression of estrogen receptors in the glands and stroma of the endometrium is observed, which does not depend on the anthropometric parameters of the patients. A direct correlation between the expression of estrogen receptors in the epithelium and the stroma of the endometrium was established. The obtained results can serve as criteria for a differentiated approach to selecting treatment tactics for women with hyperplastic processes of the endometrium.

Tags:

endometrial hyperplasia, endometrial hyperplastic processes, endometrial polyp, estrogen receptors, immunohistochemistry

Bibliography:

  1. Sanderson PA, Critchley HO, Williams AR, Arends MJ, Saunders PT. New concepts for an old problem: the diagnosis of endometrial hyperplasia. Hum Reprod Update. 2017 Mar 1;23(2):232-254. DOI: 10.1093/humupd/dmw042.
  2. Chandra V, Kim JJ, Benbrook DM, Dwivedi A, Rai R. Therapeutic options for management of endometrial hyperplasia. J Gynecol Oncol. 2016 Jan;27(1):e8. DOI: 10.3802/jgo.2016.27.e8.
  3. Travaglino A, Raffone A, Saccone G, Insabato L, Mollo A, De Placido G, et al. Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: A systematic review. Acta Obstet Gynecol Scand. 2019 Sep;98(9):1086-1099. DOI: 10.1111/aogs. 13587.
  4. Goncharenko VM, Beniuk VA, Kalenska OV, Demchenko OM, Spivak MY, Bubnov RV. Predictive diagnosis of endometrial hyperplasia and personalized therapeutic strategy in women of fertile age. EPMA J. 2013 Dec 6;4(1):24. DOI: 10.1186/1878-5085-4-24.
  5. Doherty MT, Sanni OB, Coleman HG, Cardwell CR, McCluggage WG, Quinn D, et al. Concurrent and future risk of endometrial cancer in women with endometrial hyperplasia: A systematic review and meta-analysis. PLoS One. 2020 Apr 28;15(4):e0232231. DOI: 10.1371/ journal.pone.0232231.
  6. Hutt S, Tailor A, Ellis P, Michael A, Butler-Manuel S, Chatterjee J. The role of biomarkers in endometrial cancer and hyperplasia: a literature review. Acta Oncol. 2019 Mar;58(3):342-352. DOI: 10.1080/0284186X.2018.1540886.
  7. Lyndin M, Kravtsova O, Sikora K, Lyndina Y, Kuzenko Y, Awuah WA, et al. COX2 Effects on endometrial carcinomas progression. Pathol Res Pract. 2022 Aug 17;238:154082. DOI: 10.1016/j.prp.2022.154082.
  8. Nees LK, Heublein S, Steinmacher S, Juhasz-Böss I, Brucker S, Tempfer CB, et al. Endometrial hyperplasia as a risk factor of endometrial cancer. Arch Gynecol Obstet. 2022 Aug;306(2):407-421. DOI: 10.1007/s00404-021-06380-5.
  9. Mills AM, Longacre TA. Endometrial hyperplasia. Semin Diagn Pathol. 2010 Nov;27(4):199-214. DOI: 10.1053/j.semdp.2010.09.002.
  10. Yu K, Huang ZY, Xu XL, Li J, Fu XW, Deng SL. Estrogen Receptor Function: Impact on the Human Endometrium. Front Endocrinol (Lausanne). 2022 Feb 28;13:827724. DOI: 10.3389/fendo.2022.827724.
  11. Raffone A, Travaglino A, Saccone G, Mollo A, De Placido G, Insabato L, et al. Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2019 Aug;98(8):976-987. DOI: 10.1111/aogs.13586.
  12. Bircan S, Ensari A, Ozturk S, Erdogan N, Dundar I, Ortac F. Immunohistochemical analysis of c-myc, c-jun and estrogen receptor in normal, hyperplastic and neoplastic endometrium. Pathol Oncol Res. 2005;11(1):32-9. DOI: 10.1007/BF03032403.
  13. Masjeed NMA, Khandeparkar SGS, Joshi AR, Kulkarni MM, Pandya N. Immunohistochemical Study of ER, PR, Ki67 and p53 in Endometrial Hyperplasias and Endometrial Carcinomas. J Clin Diagn Res. 2017 Aug;11(8):EC31-EC34. DOI: 10.7860/JCDR/2017/28750.10475.
  14. Kuźmycz O, Stączek P. Prospects of NSAIDs administration as double-edged agents against endometrial cancer and pathological species of the uterine microbiome. Cancer Biol Ther. 2020 Jun 2;21(6):486-494. DOI: 10.1080/15384047.2020.1736483.
  15. Chatzipantelis P, Koukourakis M, Balaska K, Giatromanolaki A. Endometrial Stromal Expression of ER, PR, and B-Catenin Toward Differentiating Hyperplasia Diagnoses. Int J Surg Pathol. 2022 Aug;30(5):492-498. DOI: 10.1177/10668969211065110.
  16. Antunes AJr, Vassallo J, Pinheiro A, Leão R, Neto AM, Costa-Paiva L. Immunohistochemical expression of estrogen and progesterone receptors in endometrial polyps: A comparison between benign and malignant polyps in postmenopausal patients. Oncol Lett. 2014 Jun;7(6):1944-1950. DOI: 10.3892/ol.2014.2004.
  17. Peres GF, Spadoto-Dias D, Bueloni-Dias FN, Leite NJ, Elias LV, Domingues MAC, et al. Immunohistochemical expression of hormone receptors, Ki-67, endoglin (CD105), claudins 3 and 4, MMP-2 and -9 in endometrial polyps and endometrial cancer type I. Onco Targets Ther. 2018 Jul 9;11:3949-3958. DOI: 10.2147/OTT.S160014.
  18. Lopes RG, Baracat EC, de Albuquerque Neto LC, Ramos JF, Yatabe S, Depesr DB, et al. Analysis of estrogen – and progesterone-receptor expression in endometrial polyps. J Minim Invasive Gynecol. 2007 May-Jun;14(3):300-3. DOI: 10.1016/j.jmig.2006.10.022.
  19. Ye Y, Wang X, Jeschke U, von Schönfeldt V. COX-2-PGE2-EPs in gynecological cancers. Arch Gynecol Obstet. 2020 Jun;301(6):1365- 1375. DOI: 10.1007/s00404-020-05559-6.
  20. Singh P, Singh P, Chaurasia A, Dhingra V, Misra V. Expression of ERα and PR in Various Morphological Patterns of Abnormal Uterine Bleeding-Endometrial causes in Reproductive Age Group. J Clin Diagn Res. 2016 Aug;10(8):EC06-9. DOI: 10.7860/JCDR/2016/19565.8290.

Publication of the article:

«Bulletin of problems biology and medicine», 2023 Issue 2, 169, 415-423 pages, index UDC 616-091

DOI:

10.29254/2077-4214-2023-2-169-415-423

2023 Issue 2, 169
endometrial hyperplasia endometrial hyperplastic processes endometrial polyp estrogen receptors immunohistochemistry
29.06.2023
Was this article helpful?
5
4